Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 6/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062543 | 1.00 | PREP (0.41) | PREPACEF2F10PLG | |
| SCHEMBL6062550 | 1.00 | PREP (0.41) | PREPACEF2F10PLG | |
| SCHEMBL8294395 | 0.80 | PREP (0.41) | PREPF2F10PRSS1 | |
| SCHEMBL8270263 | 0.80 | PREP (0.41) | PREPF2F10PRSS1 | |
| SCHEMBL2981812 | 0.80 | PREP (0.41) | PREPF2F10PRSS1 | |
| SCHEMBL30008738 | 0.77 | CASP3 (0.41) | ACEF2F10PLGPRSS1 | |
| SCHEMBL6062493 | 0.77 | PREP (0.64) | PREPDPP4 | |
| SCHEMBL6062491 | 0.77 | PREP (0.64) | PREPDPP4 | |
| SCHEMBL6063678 | 0.77 | PREP (0.64) | PREPDPP4 | |
| SCHEMBL12495203 | 0.77 | ACE (0.53) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008957-B2 | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-07 | — | — | US | disclosed |
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | CYP11B2, GOT2, CYP11B1 | PREP 1516/4885ACE 371/4885F2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.